RT Journal Article
SR Electronic
T1 COX-2 as a potential biomarker and therapeutic target in melanoma
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 20
OP 31
DO 10.20892/j.issn.2095-3941.2019.0339
VO 17
IS 1
A1 Diana Valentina Tudor
A1 Ioana Bâldea
A1 Mihai Lupu
A1 Teodor Kacso
A1 Eniko Kutasi
A1 Andreea Hopârtean
A1 Roland Stretea
A1 Adriana Gabriela Filip
YR 2020
UL http://www.cancerbiomed.org/content/17/1/20.abstract
AB With a constantly increasing incidence, cutaneous melanoma has raised the need for a better understanding of its complex microenvironment that may further guide therapeutic options. Melanoma is a model tumor in immuno-oncology. Inflammation represents an important hallmark of cancer capable of inducing and sustaining tumor development. The inflammatory process also orchestrates the adaptative immunosuppression of tumor cells that helps them to evade immune destruction. Besides its role in proliferation, angiogenesis, and apoptosis, cyclooxygenase-2 (COX-2) is a well-known promoter of immune suppression in melanoma. COX-2 inhibitors are closely involved in this condition. This review attempts to answer two controversial questions: is COX-2 a valuable prognostic factor? Among all COX-2 inhibitors, is celecoxib a suitable adjuvant in melanoma therapy?